Background/Objectives: This single-center analysis evaluated the number of potential candidates for endocrine-based oral maintenance therapy in a real-world setting, focusing on three therapeutic agents, namely, olaparib, abemaciclib, and ribociclib, for patients with hormone receptor-positive HER2-negative early breast cancer. Methods: All breast cancer cases from the past 10 years (n= 3230) that underwent treatment at the certified Breast Cancer Center of the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Lübeck Campus, were analyzed. Results: Of a total of 2038 patients with HR+ HER2− eBC, 685 patients (33.6%) qualified for one or more of the three agents—olaparib, abemaciclib, and ribociclib. Of these 685 patients, 523 patients (76.4%) had node-positive and 162 (23.6%) node-negative disease. Moreover, 368 patients (18.1% of a total of 2038 patients with HR+ HER2− eBC) were eligible exclusively for ribociclib, including all node-negative patients. A total of 141 patients (6.9%) met the criteria for all three agents. In contrast, 1353 patients (66.4%) had no indication for combined endocrine therapy. Conclusions: To our knowledge, this is the largest analysis addressing all three therapeutic strategies for combined endocrine therapy. The broad indication criteria of the NATALEE study may increase clinic workloads due to more frequent physician/patient interactions. It also remains unclear how therapy recommendations will influence actual treatment, as increased visits and potential side effects could affect patient compliance and adherence.
背景/目的：本单中心分析评估了真实世界环境中激素受体阳性HER2阴性早期乳腺癌患者中适合接受内分泌口服维持治疗的潜在候选者数量，重点关注奥拉帕利、阿贝西利和瑞博西利三种治疗药物。方法：分析了过去十年间（n=3230）在石勒苏益格-荷尔斯泰因大学医院吕贝克院区妇产科认证乳腺癌中心接受治疗的所有乳腺癌病例。结果：在2038例HR+ HER2−早期乳腺癌患者中，685例（33.6%）符合奥拉帕利、阿贝西利和瑞博西利三种药物中一种或多种的适用标准。在这685例患者中，523例（76.4%）为淋巴结阳性，162例（23.6%）为淋巴结阴性。此外，368例患者（占2038例HR+ HER2−早期乳腺癌患者的18.1%）仅符合瑞博西利适用标准，其中包括所有淋巴结阴性患者。共有141例患者（6.9%）同时满足三种药物的适用标准。相比之下，1353例患者（66.4%）无联合内分泌治疗指征。结论：据我们所知，这是目前针对联合内分泌治疗三种治疗策略的最大规模分析。NATALEE研究广泛的适应症标准可能因更频繁的医患互动而增加临床工作量。目前尚不清楚治疗建议将如何影响实际治疗，因为就诊次数增加和潜在副作用可能影响患者的治疗依从性和持续性。
Oral Maintenance Therapy in Early Breast Cancer—How Many Patients Are Potential Candidates?
肿瘤(癌症)患者之家